Nabarun DASGUPTA<br>
*Curriculum Vita*<be>

Dr. Nabarun Dasgupta is an epidemiologist.

# Personal
Nabarun Dasgupta, MPH, PhD<br>
nab@unc.edu<br>
+1-919-260-3808<br>
Location: Raleigh, North Carolina, United States<br>
LinkedIn | Twitter<be>

# Education
+ **University of North Carolina at Chapel Hill**, US<br>
 	2013 Doctor of Philosophy (PhD)<br>
	Gillings School of Global Public Health<br>
	Department of Epidemiology (pharmacoepidemiology)<br>
+ **Yale University**, New Haven, Connecticut, US<br>
	2003 Master of Public Health (MPH)<br>
	Epidemiology of Microbial Diseases<br>
+ **Princeton University**, Princeton, New Jersey, US<br>
	2001 Bachelor of Arts (BA)<br>
	Molecular Biology (virology)<br>

# Professional Experience
## Full-time Positions
2017-present: Senior Scientist<br>
							Injury Prevention Research Center<br>
							University of North Carolina at Chapel Hill<br>
Epidemico
Project Lazarus

## Consulting
+ RADARS
+ Pinney
+ WHO

## Internships
WHO
+ 2002 – 2003	Field Researcher, Yale Public Health, New Haven, CT
+ 1999		Laboratory Assistant, Miami Project to Cure Paralysis, Miami, FL
+ 1998		Scientific Intern, The Scripps Research Institute, La Jolla, CA
+ 1997 – 2001	Independent Research, Virology, Princeton University, Princeton, NJ
+ 1993 – 1997	Summer Intern, Veterinary Virology, IDEXX Laboratories, Westbrook, ME

# Honors
# Bibliography and products of scholarship
## Books & Chapters (show author order and include pages)
<ol reversed>
  <li>Christian JB, Dasgupta N, Jordan M, Juneja M, Nilsen W, Reites J. (2018) Digital Health and Patient Registries: Today, Tomorrow, and the Future. (2018) In Registries for Evaluating Patient Outcomes: A User’s Guide 3rd Edition, Addendum. Gliklich RE, Dreyer NA, Leavy MB, Christian JB editors. Agency for Healthcare Research and Quality Publication No. 17(18)-EHC013-EF.
</li>
  <li>Dasgupta N. Control of Diseases of the Air and Land. (2009). In Environmental Engineering: Prevention and Response to Water-, Food-, Soil-, and Air-borne Disease and Illness, Vol. 2, Sixth Edition. Agardy FJ, Salvato JA, Nemerow NL, eds. John Wiley & Sons: 175-211. 
</li>
  <li>Dasgupta N. Foodborne Diseases. (2009). In Environmental Engineering: Prevention and Response to Water-, Food-, Soil-, and Air-borne Disease and Illness, Vol. 2, Sixth Edition. Agardy FJ, Salvato JA, Nemerow NL, eds. John Wiley & Sons: 175-211. 
</li>
  <li>Dasgupta N., M. Jonsson Funk, et al. (2008). Comparing Unintentional Opioid Poisoning Mortality in Metropolitan and Non-Metropolitan Counties, United States, 1999Ð2003. Geography and Drug Addiction. Y. Thomas, ed. New York, Springer: 179-195.
</li>
  </ol>



	III. PROFESSIONAL EXPERIENCE

2013 – present	Senior Research Scientist, Injury Prevention Research Center, UNC-CH
2005 – present	Consultant Scientist, RADARS® System, Denver Health & Hospitals, CO
2017 – 2018	Senior Scientist, Eshelman School of Pharmacy, UNC-CH
2016		Scientific Advisor, Booz Allen Hamilton, Rockville, MD
2007 – 2016	Co-founder and Chief Science Officer, Epidemico, Inc., Boston, MA
2009 – 2016	Contract Research Consultant, Pinney Associates, Bethesda, MD
2008 – 2014	Co-founder, Project Lazarus, Wilkes County, NC 
2006, 2009	Intern & Consultant: World Health Organization (WHO), Geneva, Switzerland
2005 – 2007	Research Associate, Department of Epidemiology, UNC Gillings Schools of Global Public Health, University of North Carolina at Chapel Hill
2004 – 2005	Associate Epidemiologist, Purdue Pharma LP, Stamford, CT
2003 – 2004	Clinical Risk Assessment Specialist, Purdue Pharma LP, Stamford, CT



IV.  HONORS

1.	Barbara Sorensen Hulka Dissertation Award, Department of Epidemiology, UNC-CH 2014
2.	Abstract of the Year (Law), American Association of Public Health 2013
3.	Best Student Abstract (ATOD), American Association of Public Health 2007
	V. BIBLIOGRAPHY 

(a) Articles in Peer-Reviewed Journals   

<ol reversed>
  <li>van Stekelenborg J, Ellenius J, Maskell S, Bergvall T, Caster O, Dasgupta N, Dietrich J, Gama S, Lewis D, Newbould V, Brosch S, Pierce CE, Powell C, Ptaszyńska-Neophytou A, Wiśniewski AFZ, Tregunno P, Norén GN, Pirmohamed M. Recommendations for the use of Social Media in Pharmacovigilance: Lessons from IMI WEB-RADR. Drug Safety, in press.
</li>
  <li>Young JC, Jonsson Funk MJ, Dasgupta N. Medical Use of Long-term Extended-Release Opioid Analgesics in Commercially Insured Adults in the United States. Pain Medicine, In press.</li>
  <li>Pierce CE, de Vries ST, Bodin-Parssinen S, Härmark L, Tregunno P, Lewis DJ, Maskell S, Van Eemeren R, Ptaszynska-Neophytou A, Newbould V, Dasgupta N, Wisniewski AFZ, Gama S, Mol PGM. Recommendations on the Use of Mobile Applications for the Collection and Communication of Pharmaceutical Product Safety Information: Lessons from IMI WEB-RADR. Drug Safety. 2019 Apr;42(4):477-489. doi: 10.1007/s40264-019-00813-6.</li>
</ol>

1.	2.	
3.	
4.	Patel R, Belousov M, Jani M, Dasgupta N, Winokur C, Nenadic G, Dixon WG. Frequent discussion of insomnia and weight gain with glucocorticoid therapy: An analysis of Twitter posts. NPJ Digit Med. 2018 Feb 12;1. doi: 10.1038/s41746-017-0007-z. PMID: 30740536 
5.	Dasgupta N, Schwarz J, Hennessy S, Ertefaie A, Dart RC. Causal inference for evaluating prescription opioid abuse using trend-in-trend design. Pharmacoepidemiol Drug Saf. 2019 Feb 3. doi: 10.1002/pds.4736. [Epub ahead of print] PMID: 30714239
6.	Alexandridis AA, Dasgupta N, McCort AD, Ringwalt CL, Rosamond WD, Chelminski PR, Marshall SW. Associations between implementation of Project Lazarus and opioid analgesic dispensing and buprenorphine utilization in North Carolina, 2009-2014. Inj Epidemiol. 2019 Jan 21;6(1):2. doi: 10.1186/s40621-018-0179-2. PMID: 30663005 
7.	Iwanicki JL, Severtson SG, Margolin Z, Dasgupta N, Green JL, Dart RC. Consistency Between Opioid-Related Mortality Trends Derived From Poison Center and National Vital Statistics System, United States, 2006-2016. Am J Public Health. 2018 Dec;108(12):1639-1645. doi: 10.2105/AJPH.2018.304728. PMID: 30403501
8.	Dasgupta N, Saucier R, Wolfe D. Authors' Response to Silverman and Colleagues' Comment on "Review of Case Narratives from Fatal Overdoses Associated with Injectable Naltrexone for Opioid Dependence". Drug Saf. 2018 Oct;41(10):995-997. doi: 10.1007/s40264-018-0692-9.
9.	Lebin JA, Murphy DL, Severtson SG, Bau GE, Dasgupta N, Dart RC. Scoring the best deal: Quantity discounts and street price variation of diverted oxycodone and oxymorphone. Pharmacoepidemiol Drug Saf. DOI: 10.1002/pds.4558. Epub ahead of print.
10.	Murphy DL, Lebin JA, Severtson SG, Olsen HA, Dasgupta N, Dart RC. Comparative rates of mortality and serious adverse effects among commonly prescribed opioid analgesics. Drug Saf. 2018 Aug; 41(8): 787-795. DOI: 10.1007/s40264-018-0660-4.
11.	Dasgupta, N. He is the object of information: The intersection of big data and the opioid crisis. American Journal of Public Health. 108(9): 1122-1123. 2018   PMID: 30089004
12.	Dasgupta, N. Evaluating difficult-to-crush opioids in the community. The Lancet Psychiatry. 5(2): 98-100 2018. PMID:29336949
13.	Dasgupta, N., Beletsky, L., Ciccarone, D. Opioid crisis: No easy fix to its social and economic determinants. American Journal of Public Health 108(2): 182-186. 2018
PMID:29267060
14.	Saucier, R., Wolfe, D., Dasgupta, N. Review of case narratives from fatal overdoses associated with injectable Naltrexone for opioid dependence. Drug Safety. 41(10): 981-988. 2018 PMID:29560596
15.	Ringwalt, C., Sanford, C., Dasgupta, N., Alexandridis, A.A., McCort, A., Proescholdbell, S.K., Sachdeva, N., Mack, K. Community readiness to prevent opioid overdose. Health Promotion Practice. 19(5):745-755. 2018   PMCID: PMC6070422
16.	Young, J.C., Lund, J.L., Dasgupta, N., Funk, M.J. Opioid tolerance and clinically recognized opioid poisoning among patients prescribed extended‐release long‐acting opioids. Pharmacoepidemiology and Drug Safety. 2018 Jun 11. [Epub ahead of print] https://doi.org/10.1002/pds.4572
17.	Ranapurwala, S.I., Naumann, R.B., Austin, A., Dasgupta, N., Marshall, S.W. Methodologic limitations of prescription opioid safety research and recommendations for improving the evidence base. Pharmacoepidemiology and Drug Safety. 2018 Jun 3. [Epub ahead of print] https://doi.org/10.1002/pds.4564
18.	Murphy, D.L., Lebin, J.A., Severtson, S.G., Olsen, H.A., Dasgupta, N., Dart, R.C. Comparative rates of mortality and serious adverse effects among commonly prescribed opioid analgesics. Drug Safety. 41(8): 787-795. 2018 https://doi.org/10.1007/s40264-018-0660-4
19.	Lebin, J.A., Murphy, D.L., Severtson, S.G., Bau, G.E., Dasgupta, N., Dart, R.C. Scoring the best deal: Quantity discounts and street price variation of diverted Oxycodone and Oxymorphone. Pharmacoepidemiology and Drug Safety. 2018 May 15. [Epub ahead of print] https://doi.org/10.1002/pds.4558
20.	Alexandridis, A.A., McCort, A., Ringwalt, C.L., Sachdeva, N., Sanford, C., Marshall, S.W., Mack, K., Dasgupta, N. A statewide evaluation of seven strategies to reduce opioid overdose in North Carolina. Injury Prevention. 24(1): 48-54. 2018 PMCID: PMC5795575
21.	Dasgupta, N., Gilbert, M. Commentary van der Gouwe et al. (2017): Drug‐testing services and cryptomarkets come of age. Addiction. 112(4): 649-650. 2017 https://doi.org/10.1111/add.13771
22.	Gilbert, M., Dasgupta, N. Silicon to syringe: Cryptomarkets and disruptive innovation in opioid supply chains. International Journal of Drug Policy. 46:160-167. 2017 https://doi.org/10/1016/j.drugpo.2017.05.052
23.	Dart, R.C., Iwanicki, J.L., Dasgupta, N., Cicero, T.J., Schnoll, S.H. Do abuse deterrent opioid formulations work? Journal of Opioid Management. 13(6): 365-378. 2017 https://doi.org/10.5055/jom.2017.0415
24.	Bonnemann, C., Boutin, M., Brais, B., Buccella, F., Burghes, A., Coffey, C., Dasgupta, N., et al. Facilitating orphan drug development: Proceedings of the TREAT-NMD International Conference, December 2015, Washington, DC, USA. Neuromuscular Disorders. 27(7): 693-701. 2017 https://doi.org/10.1016/j.nmd.2017.02.013
25.	Pierce, C.E., Bouri K., Pamer, C., Proestel, S., Rodriguez, H.W., Van Le, H., Freifeld, C.C., Brownstein, J.S., Walderhaug, M., Edwards, I.R., Dasgupta, N. Evaluation of Facebook and Twitter monitoring to detect safety signals for medical products: An analysis of recent FDA safety alerts. Drug Safety. 40(4): 317-331. 2017 https://doi.org/10.1007/s40264-016-0491-0
26.	Anderson, L.S., Bell, H.G., Gilbert, M., Davidson, J.E., Winter, C., Barratt, M.J., Win, B., Painter, J.L., Menone, C., Sayegh, J., Dasgupta, N. Using social listening data to monitor misuse and nonmedical use of Bupropion: A content analysis. JMIR Public Health and Surveillance. 3(1): e6. 2017 PMCID: PMC5311422
27.	Dasgupta, N., Funk, M.J., Proescholdbell, S.K., Hirsch, A., Ribisl, K.M., Marshall, S. Cohort study of the impact of high-dose opioid analgesics on overdose mortality. Pain Medicine. 17(1): 85-98. 2016 https://doi.org/10.1111/pme.1207
28.	Severtson, S.G., Ellis, M.S., Kurtz, S.P., Rosenblum, A., Cicero, T.J., Parrino, M.W., Gilbert, M.K., Buttram, M.E., Dasgupta, N., Bartelson, B., Green, J.L., Dart, R.C. Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release Oxycodone. Drug and Alcohol Dependence. 168: 219-229. https://doi.org/10.1016/j.drugalcdep.2016.09.018
29.	Powell, G.E., Seifert, H.A., Reblin, T., Burstein, P.J., Blowers, J., Menius, J.A., Painter, J.L., Thomas, M., Pierce, C.E., Rodriguez, H.W., Brownstein, J.S., Frefield, C.C., Bell, H.G., Dasgupta, N. Social media listening for routine post-marketing safety surveillance. Drug Safety. 39(5): 443-454. 2016 https://doi.org/10.1007/s40264-0150385-6
30.	Dasgupta, N., Raymond, D. Commentary on Degenhardt et al (2015): a new formulation for research. Addiction. 110(2): 238-239. 2015 https://doi.org/10.1111/add.12812
31.	Conover, M.M., Howell, J.O., Wu, J.M., Kinlaw, A.C., Dasgupta, N., Funk, M.J. Incidence of opioid‐managed pelvic pain after hysteroscopic sterilization versus laparoscopic sterilization, US 2005‐2012. Pharmacoepidemiology and Drug Safety. 24(8): 875-884. 2015 PMCID: PMC4527877
32.	Webster, L., Reisfield, G.M., Dasgupta, N. Eight principles for safer opioid prescribing and cautions with benzodiazepines. Postgraduate Medicine. 127(1): 27-32. 2015 https://doi.org/10.10800/00325481.2015.993276
33.	Dart, R.C., Surratt, H.L., Le Lait, M.C., Stivers, Y., Bebarta, V.S., Freifeld, C.C., Brownstein, J.S., Burke, J.J., Kurtz, S.P., Dasgupta, N. Diversion and illicit sale of extended release Tapentadol in the United States. Pain Medicine. 17(8): 1490-1496. 2015 PMCID: PMC4975014
34.	Bahk, C.Y., Goshgarian, M., Donahue, K., Freifeld, C.C., Menone, C.M., Pierce, C.E., Rodriguez, H., Brownstein, J.S., Furberg, R., Dasgupta, N. Increasing patient engagement in pharmacovigilance through online community outreach and mobile reporting applications: An analysis of adverse event reporting for the Essure device in the US. Pharmaceutical Medicine. 29(6): 331-340. 2015 PMCID: PMC4656696
35.	Dasgupta, N., Creppage, K., Austin, A., Ringwalt, C., Sanford, C., Proescholdbell, S.K. Observed transition from opioid analgesic deaths toward heroin. Drug and Alcohol Dependence. 145: 238-241. 2014 https://doi.org/10.1016/j.drugaldep.2014.10.005
36.	Gerlach, K.K., Dasgupta, N., Schnoll, S.E., Henningfield, J.E. Epidemiology of stimulant misuse and abuse: Implications for future epidemiologic and neuropharmacologic research. Neuropharmacology. 87: 91-96. 2014 https://doi.org/10.1016/j.neuropharm.2014.04.020
37.	Davis, C.S., Pierce, M., Dasgupta, N. Evolution and convergence of state laws governing controlled substance prescription monitoring programs, 1998-2011. American Journal of Public Health. 104(8):1389-1395. 2014 PMCID: PMC4103230
38.	Ringwalt, C., Gugleman, H., Garrettson, M., Dasgupta, N., Chung, A.E., Proescholdbell, S.K., Skinner, A.C. Differential prescribing of opioid analgesics according to physician specialty for Medicaid patients with chronic noncancer pain diagnoses. Pain Research and Management. 19(4): 179-185. 2014 PMCID: PMC4158932
39.	Hirsch, A., Proescholdbell, S.K., Bronson W, Dasgupta, N. Prescription histories and dose strengths associated with overdose deaths. Pain Medicine. 15(7):1187-1195. 2014
40.	Freifeld, C.C., Brownstein, J.S., Menone, C.M., Bao, W., Filice, R., Kass-Hout, T., Dasgupta N. Digital drug safety surveillance: Monitoring pharmaceutical products in Twitter. Drug Safety. 37(5): 343-350. 2014 PMCID: PMC4013443
41.	Dasgupta, N., Freifeld, C., Brownstein, J.S., Menone, C.M., Surratt, H., Poppish, L., Green, J.L., Lavonas, E.J., Dart, R.C. Crowdsourcing black market prices for prescription opioids. Journal of Medical Internet Research. 15(8): e178. 2013 PMCID: PMC3758048
42.	Brason, A.S., Roe, C., Dasgupta, N. Project Lazarus: An innovative community response to prescription drug overdose. North Carolina Medical Journal. 74(3): 259. 2013
43.	Sembower, M.A., Ertischek, M.D., Buchholtz, C., Dasgupta, N., Schnoll, S.H. Surveillance of diversion and nonmedical use of extended-release prescription amphetamine and oral methylphenidate in the United States. Journal of Addictive Diseases. 32(1): 26-38. 2013 PMCID: PMC3630455
44.	Dasgupta, N., Davis, J., Jonsson, F.M., Dart, R. Using poison center exposure calls to predict methadone poisoning deaths. PLoS One. 7(7): e41181. 2012 PMCID: PMC3400615
45.	Heimer, R., Dasgupta, N., Irwin, K.S., Kinzly, M., Harvey, A.P., Givens, A., Grau, L.E. Chronic pain, addiction severity, and misuse of opioids in Cumberland County, Maine. Addictive Behaviors. 37(3): 346-349. 2012 https://doi.org/10.1016/j.addbeh.2011.11.017
46.	Turk, D.C., O’Connor, A.B., Dworkin, R.H., Chaudhry, A., Katz, N.P., Adams, E.H., Brownstein, J.S., Comer, S.D., Dart, R., Dasgupta, N., et al. Research design considerations for clinical studies of abuse-deterrent opioid analgesics: IMMPACT recommendations. Pain. 153 (10): 1997-2008. 2012 PMCID: PMC3617214
47.	Dasgupta, N., Henningfield, J.E., Ertischek, M.D., Schnoll, S.H. When drugs in the same controlled substance schedule differ in real-world abuse, should they be differentiated in labeling? Drug and Alcohol Dependence. 119(1-2): e1-e4. 2011 https://doi.org/10.1016/j.drugalcdep.2011.05.013
48.	Dart, R.C., Dasgupta, N., Bailey, J.E., Spiller, H.A. Interpreting poison center call volume associated with Tramadol. Annals of Pharmacotherapy. 45(3): 424-424. 2011 https://doi.org/10.1345/aph.1P064b
49.	Webster, L.R., Dasgupta, N. Obtaining adequate data to determine causes of opioid-related overdose deaths. Pain Medicine. 12 Suppl 2: S86-S92. 2011 https://doi.org/10.1111/j.1526-4637.2011.01132.x
50.	Wolfe, D., Carrieri, M.P., Dasgupta, N., Wodak, A., Newman, R., Bruce, R.D. Concerns about injectable naltrexone for opioid dependence. Lancet (London, England). 377(9776): 1468-1470. 2011 https://doi.org/10.1016/S0140-6736(10)62056-9
51.	Webster, L.R., Cochella, S., Dasgupta, N., Fakata, K.L., Fine, P.G., Fishman, S.M., Grey, T., Johnson, E.M., Lee, L.K., Passik, S.D., et al. An analysis of the root causes for opioid-related overdose deaths in the United States. Pain Medicine. 12 Suppl 2: S26-S35. 2011 https://doi.org/10.1111/j.1526-4637.2011.01134.x
52.	Roux, P., Carrieri, M.P., Dasgupta, N. Reducing harm from injecting pharmaceutical tablet or capsule material by injecting drug users. Drug and Alcohol Review. 30(3): 287-290. 2011 https://doi.org/10.1111/j.1465-3362.2011.00285.x
53.	Dasgupta, N., Bailey, E.J., Cicero, T., Inciardi, J., Parrino, M., Rosenblum, A., Dart, R.C. Post-marketing surveillance of methadone and buprenorphine in the United States. Pain Medicine. 11(7):1078-1091. 2010 https://doi.org/10.1111/j.1526-4637.2010.0877.x
54.	Kramer, E.D., Dasgupta, N. Embolic stroke associated with injection of buprenorphine tablets. Neurology. 74(10): 863-864. 2010 https://doi.org/10.1212/WNL.0b013e3181d2b5f6
55.	Dasgupta, N., Schnoll, S.H. Signal detection in post-marketing surveillance for controlled substances. Drug and Alcohol Dependence. 105 Suppl 1: S33-S41. 2009 https://doi.org/10.1016/j.drugalcdep.2009.05.019
56.	Dasgupta, N., Mandl, K.D., Brownstein, J.S. Breaking the news or fueling the epidemic? Temporal association between news media report volume and opioid-related mortality. PloS One. 4(11): e7758. 2009 PMCID: PMC2771896
57.	Grau, L.E., Dasgupta, N., Harvey, A.P., Irwin, K., Givens, A., Kinzly, M.L., Heimer, R. Illicit use of opioids: Is OxyContin® a “gateway drug?”. American Journal on Addictions. 16 (3):166-173. 2007 https://doi.org/10.1080/10550490701375293
58.	Thomas, J.C., Dasgupta, N., Martinot, A. Ethics in a pandemic: A survey of the state pandemic influenza plans. American Journal of Public Health. 97 Suppl 1: S26-S31. 2007 PMCID: PMC1854979
59.	Dasgupta, N., Kramer, E.D., Zalman, M.A., Carino, S., Smith, M.Y., Haddox, J.D., Wright C 4th. Association between non-medical and prescriptive usage of opioids. Drug and Alcohol Dependence. 82(2): 135-142. 2006 https://doi.org/10.1016/j.drugalcdep.2005.08.019
60.	Huang S, Reddy V, Dasgupta N, Nemerow GR. A single amino acid in the adenovirus type 37 fiber confers binding to human conjunctival cells. Journal of Virology. 1999 Apr;73(4):2798-802. PMID: 10074127

(b) Technical Reports from Organizations
61.	Severtson SG, Schwarz J, Dasgupta N, Dart RC (2018). Rates of Abuse for Opioids with Low Dispensing are Overestimated due to Careless Response Patterns on Treatment Center Program Surveys. RADARS® System Technical Report, 2018-Q2.
62.	Black JC, Bau G, Bucher Bartelson B, Dasgupta N, Dart RC, Green JL (2017). Comparison of Population Rate Trends between the National Vital Statistics System and the RADARS® System Medical Examiner Program. RADARS® System Technical Report, 2017-Q2.
63.	Dasgupta N, Bailey JE, Dart RC (2017). Implications of Declining Poison Center Case Volume on Drug Abuse Trend Monitoring. RADARS® System Technical Report, 2017-Q3.
64.	Lebin JA, Murphy DL, Severtson SG, Dasgupta N, Dart RC (2015). Reduced Street Price and Quantity Discounts for Diverted Extended Release OxyContin ER and Opana ER Following Crush Resistant Reformulation. RADARS® System Technical Report, 2015-Q2.
65.	Dart RC, Martinez E, Severtson SG, Menone CM, Dasgupta N (2014). Appearance of Canadian Oxycodone Extended Release Products in the United States. RADARS System Technical Report, 2014-Q1. 
66.	Report of the Thirty-fifth meeting of the Expert Committee on Drug Dependence, 2012. World Health Organization, Geneva.
67.	Dasgupta N, Brason FI, Albert S, Sanford CP. Project Lazarus: Overdose prevention and responsible pain management. In NCMB Forum 2008 (Vol. 1, pp. 8-12).

(c) Book Chapters (peer reviewed)
68.	Dasgupta N., M. Jonsson Funk, et al. (2008). Comparing Unintentional Opioid Poisoning Mortality in Metropolitan and Non-Metropolitan Counties, United States, 1999Ð2003. Geography and Drug Addiction. Y. Thomas, ed. New York, Springer: 179-195.
69.	Dasgupta N. Foodborne Diseases. (2009). In Environmental Engineering: Prevention and Response to Water-, Food-, Soil-, and Air-borne Disease and Illness, Vol. 2, Sixth Edition. Agardy FJ, Salvato JA, Nemerow NL, eds. John Wiley & Sons: 175-211. 
70.	Dasgupta N. Control of Diseases of the Air and Land. (2009). In Environmental Engineering: Prevention and Response to Water-, Food-, Soil-, and Air-borne Disease and Illness, Vol. 2, Sixth Edition. Agardy FJ, Salvato JA, Nemerow NL, eds. John Wiley & Sons: 175-211. 
71.	Christian JB, Dasgupta N, Jordan M, Juneja M, Nilsen W, Reites J. (2018) Digital Health and Patient Registries: Today, Tomorrow, and the Future. (2018) In Registries for Evaluating Patient Outcomes: A User’s Guide 3rd Edition, Addendum. Gliklich RE, Dreyer NA, Leavy MB, Christian JB editors. Agency for Healthcare Research and Quality Publication No. 17(18)-EHC013-EF.

Scientific Conferences

1.	Invited Presentations [Plenary or larger, in non-commercial convenings]

1.	Dasgupta N. RADARS® System Subutex & Suboxone: How Much is Prescribed vs. Abuse/Diversion Reports. Center for Substance Abuse Treatment. Washington, DC. February 2008.
2.	Dasgupta N. Project Lazarus: Preventing Prescription Opioid Poisoning Fatalities. New Jersey Overdose Summit, November 21, 2008.
3.	Dasgupta N. How Do We Evaluate the Effectiveness of REMS? Tufts Health Care Institute, July 24, 2009, Boston.
4.	Dasgupta N. Observational and Claims Data Studies of Abuse-related Outcomes Limitations and Prospects for Improvement. IMMPACT-X, June 3, 2009, Arlington, Virginia.
5.	Dasgupta N. Buprenorphine Data from The RADARS® System. Center for Substance Abuse Treatment. Buprenorphine Mortality - Reassessment 2010. Washington, DC. May 2010.
6.	Dasgupta, N. Dollars and Sense: What Street Prices Tell Us. National Association of Drug Diversion Investigators Annual Meeting, November 17, 2010, Indianapolis. 
7.	Dasgupta N, Surratt H. One Year Later: Evaluating the OxyContin reformulation using street prices. National Association of Drug Diversion Investigators Annual Meeting, November 16, 2011, Jacksonville, Florida. 
8.	Dasgupta N, Lewis D. Latest developments in adverse reaction reporting and communicating with patients and healthcare professionals – The MedWatcher Application, Mobile Phones and Crowdsourcing for Drug Safety Surveillance. DIA12th EudraVigilance Information Day, May 30, 2012, London.
9.	Dasgupta N. How the FDA uses mobile apps and social media monitoring to identify AEs. ICPE August 27, 2013, Montreal.
10.	Dasgupta N. Crowdsourcing as a way to evaluate drug abuse in the community. Cross-Company Abuse Liability Council’s Advancements in Abuse Potential Assessments – Building on the FDA Draft Guidance for Industry. Bethesda, MD. April 2015. 
11.	Dasgupta N. Risk of Opioid Overdose Death in North Carolina by Type of Opioid and Other Controlled Substances Prescribed. CPDD June 15, 2015, Phoenix.
12.	Dasgupta N, Pierce C. Use of social media for data mining in pharmacovigilance. International Society of Pharmacovigilance, October 27–30, 2015 Annual Meeting, Prague.
13.	Dasgupta N. Virtual Poison Center. Mid-year Meeting of the American Association of Poison Control Centers, February 24, 2016, Arlington, Virginia. 
14.	Dasgupta N. Social Listening For Safety Outcomes & Pharmacoeconomic Considerations: Has The Time Come? International Society for Pharmacoeconomics, May 24, 2016, Washington DC.
15.	Dasgupta N. Listening to the patient's voice: social media for participatory pharmacovigilance and benefits. European Conference on Rare Diseases, May 28, 2016, Edinburgh.
16.	Dasgupta N. Impact of Abuse Deterrent Opioids on Street Prices. RADARS System Annual Meeting, May 6, 2016, Washington DC.
17.	Dasgupta N. Impact of web 3.0 technologies on collection, analyses, and communication of data in pharmacovigilance. Pharmacovigilance in the 21st century: is it time for a new Erice declaration? September 16, 2016, Erice, Sicily.
18.	Dasgupta N. The Myths and Realities of the Opioid Epidemic. Association for Medical Education and Research in Substance Abuse Conference, November 3, 2017, Washington DC.
19.	Dasgupta N, Raymond D. Moving Beyond Opioids: Taking Our Work to Drug Policy. Southern Harm Reduction and Drug Policy Conference, April 25, 2018, Lake Junaluska, NC. 
20.	Dasgupta N, Schwarz J. A Causal Approach to Understanding Abuse in the Community. RADARS System Annual Meeting, May 10, 2018, Washington DC.
21.	Dasgupta N. Invited. Summer School in Digital Epidemiology, Liverpool, July 17-19, 2019.

2.	Abstracts accepted for oral presentation 

Only presentations with the RADARS System are included below. Other presentations were numerous and not routinely documented, but numbering around 8 per year from 2012 to 2019.

Dasgupta N. Challenging my illusions about the opioid crisis. Association for Medical Education and Research in Substance Abuse Annual Meeting. Washington, DC. November 2017.

Dasgupta N, Bailey JE, Dart RC, Funk MJ. Poison center exposure calls predict mortality due to prescription opioid poisoning. American Public Health Association Annual Meeting. Washington, DC. November 2007. O


3.	Abstracts accepted for poster presentation 

Only presentations with the RADARS System are included below. Other presentations were numerous and not routinely documented.

Dasgupta N, Schwarz J, Dart RC. Trend-in-trend method to analyze abuse of new and low volume opioids in the community setting. Society for Epidemiologic Research 51st Annual Meeting. Baltimore, MD. June 2018. 

Iwanicki JL, Haynes CM, Sproule B, Kurtz SP, Cicero TJ, Dasgupta N, Dart RC, Green JL. Five program system for postmarketing surveillance of prescription drug misuse. Canadian Centre on Substance Abuse Issues of Substance Conference. Calgary, Alberta. November 2017. 

May KP, Rosen T, Dasgupta N, Green JL, Dart RC. Cross-border trafficking of prescription oxycodone products manufactured in Canada. Canadian Pain Society 38th Annual Scientific Meeting. Halifax, NS. May 2017. 
Dasgupta N, Schwarz J, Dart RC. Case review of opioid-induced thrombotic thrombocytopenic purpura (TTP) from pharmacovigilance and poison centers. International Conference on Pharmacoepidemiology & Therapeutic Risk Management. Pharmacoepidemiol Drug Saf. 2017; 26(Suppl 2):634-635.

Dart RC, Goodman EM, McBride K, Margolin Z, Dasgupta N, Menone C, Green JL, Iwanicki JL. Monitoring the Street Price of Diverted Opioids in Canada with StreetRx.com. Canadian Centre on Substance Abuse Issues of Substance Conference. Montreal, Quebec. November 2015. 

Severtson SG, Besharat AC, Green JL, Dasgupta N, Ellis MS, Cicero TJ, Dart RC. Transborder trafficking of prescription opioids in Canada and the United States. Canadian Pain Society 36th Annual Scientific Meeting. Charlottetown, PEI. May 2015. 

Le Lait MC, Severtson SG, Dasgupta N, Green JL, Hall A, Dart RC. The street prices of immediate release and extended release tapentadol are lower than other Schedule II opioid tablets/capsules. College on Problems of Drug Dependence Annual Meeting, San Juan, Puerto Rico. June 2014.

West NA, Le Lait MC, Surratt H, Burke JJ, Kurtz SP, Dasgupta N, Bebarta VS, Dart RC. Diversion and illicit sale of extended release tapentadol in the United States. PAINWeek 2014. Las Vegas, NV. September 2014.

Dasgupta N, Menone CM, Dart R, Brownstein JS. Assessing abuse deterrence strategies for pharmaceuticals using crowdsourcing for black market street prices. College on Problems of Drug Dependence Annual Meeting. Palm Springs, CAL. June 2012. 

Dasgupta N, Brownstein J, Schnoll SH. Geospatial modeling of disparate data sources on prescription opioid abuse. College on Problems of Drug Dependence Annual Meeting. Orlando, FL. June 2005. 


4. Print and Online Media Mentions

Selected named mentions in news media include citations in The New York Times, CNN, Los Angeles Times, Chicago Tribune, Boston Globe, Gizmodo, and other.

1.	Neilson S. More Kids Are Getting Placed In Foster Care Because Of Parents' Drug Use. National Public Radio (NPR). Accessed July 15, 2019. https://www.npr.org/sections/health-shots/2019/07/15/741790195/more-kids-are-getting-placed-in-foster-care-because-of-parents-drug-use
2.	Willett K. UK, UNC Research Will Assist FDA in Making Opioid Regulatory Decisions. December 5, 2018. UKNOW. Accessed June 28, 2019, https://uknow.uky.edu/research/uk-unc-research-will-assist-fda-making-opioid-regulatory-decisions
3.	Poston B. Capping years of criticism, Purdue Pharma will stop promoting its opioid drugs to doctors. Los Angeles Times. February 10, 2018. Accessed June 28, 2019, https://www.latimes.com/local/lanow/la-me-ln-purdue-marketing-20180210-story.html
4.	Knopf T. Complex Pain Problems Put Patients in a Bind. October 17, 2018. North Carolina Health News. Accessed June 28, 2019, https://www.northcarolinahealthnews.org/2018/10/17/complex-pain-problems-put-patients-in-a-bind/
5.	Hamilton, K. December 21, 2017. How the GOP tax bill could lead to more opioid overdoses. VICE News. Accessed June 28, 2019, https://news.vice.com/en_us/article/43qweg/gop-tax-bill-could-lead-to-more-opioid-overdoses
6.	Gordon S. January 11, 2018. Tamper-Resistant Opioids May Not Ease Addiction Crisis: Study. Health Day. Accessed June 28, 2019, https://consumer.healthday.com/bone-and-joint-information-4/opioids-990/tamper-resistant-opioids-may-not-ease-addiction-crisis-study-730081.html
7.	Fiore, K. January 11, 2018. Abuse-Deterrent Opioid No Help in Australia. MedPage Today. Accessed June 28, 2019, https://www.medpagetoday.com/neurology/opioids/70442

8.	Ryan H, Girion L, Glover S. December 18, 2016. OxyContin goes global — “We’re only just getting started.” Los Angeles Times. Accessed June 28, 2019, https://www.latimes.com/projects/la-me-oxycontin-part3/
9.	To address opioid crisis, researchers call for focus on root causes of suffering. December 27, 2017. MedicalXpress. Accessed June 28, 2019, https://medicalxpress.com/news/2017-12-opioid-crisis-focus-root.html
10.	Firth, S. May 22, 2018. FDA Advisors Recommend Rejecting Buprenorphine Spray. MedPage Today. Accessed June 28, 2019, https://www.medpaetoday.com/painmanagement/painmanagement/73051
11.	Foley KE. January 12, 2018. Tamper-proof opioids won’t stop epidemics. Quartz. Accessed June 28, 2019, http://qz.com/1176573/do-tamper-resistant-opioids-work/
12.	MacGillis A. April 3, 2018. Addiction drug’s side effect: More overdoses? Bangor Daily News. Accessed June 28, 2019, https://bangordailynews.com/2018/04/03/news/nation/addiction-drugs-side-effect-more-overdoses
13.	Gregory T. December 21, 2017. 5 suburban counties suing drug companies over opioid epidemic. Chicago Tribune. Accessed June 28, 2019, https://www.chicagotribune.com/suburbs/ct-met-suburban-counties-sue-opioid-makers-20171221-story.html
14.	Ely K. January 16, 2018. Introduction of Tamper-Resistant Formulations of Opioids Has No Effect on Abuse Levels. AJMC. Accessed June 28, 2019, https://www.ajmc.com/newsroom/introduction-of-tamperresistant-formulations-of-opioids-has-no-effect-on-abuse-levels
15.	Poston B. February 13, 2018. Facing Mounting Lawsuits, Purdue Pharma Will Stop Promoting Opioids. Tribune News Service. Accessed June 28, 2019, https://www.governing.com/topics/health-human-services/tns-purdue-pharma-opioid-lawsuits-sell.htm
16.	NDARC Media. January 11, 2018. Tamper-resistant oxycodone tablets have no impact on overall opioid use. Accessed June 28, 2019, https://newsroom.unsw.edu.au/news/health/tamper-resistant-oxycodone-tablets-have-no-impact-overall-opioid-use
17.	Taylor T. July 22, 2018. Opioids: Brought to You by the Medical Care Industry. BBN Times. Accessed June 28, 2019, https://www.bbntimes.com/en/global-economy/opioids-brought-to-you-by-the-medical-care-industry
18.	Hoffman J. September 26, 2011. Kits Using Naloxone Revive Addicts After Opiate Overdose. The New York Times. Accessed June 28, 2019, https://www.nytimes.com/2011/09/27/health/27overdose.html
19.	Kolitz D. August 23, 2017. Why the FDA Can't Fix the Opioid Crisis. Gizmodo. Accessed June 28, 2019, https://gizmodo.com/why-the-fda-cant-fix-the-opioid-crisis-1797950053
20.	Sukkar E. Janaury 22, 2015. Searching social networks to detect adverse reactions. The Pharmaceutical Journal. Accessed June 28, 2019, https://www.pharmaceutical-journal.com/news-and-analysis/features/searching-social-networks-to-detect-adverse-reactions/20067624.article?firstPass=false
21.	Lieber M. April 13, 2018. Drop in new opioid prescriptions to benzodiazepine patients could reduce overdoses, study suggests. CNN. Accessed June 28, 2019, https://www.cnn.com/2018/04/13/health/opioid-benzodiazepine-prescription-study/index.html
22.	Cunningham PW. April 3, 2016. Model program to fight drug abuse falls flat. Washington Examiner. Accessed June 28, 2019, https://www.washingtonexaminer.com/model-program-to-fight-drug-abuse-falls-flat
23.	Abuse-Deterrent Opioids: A Business Answer To The Opioid Abuse Crisis. StrategyDoc, Seeking Alpha. September 13, 2018. Accessed June 28, 2019, https://seekingalpha.com/article/4206069-abuse-deterrent-opioids-business-answer-opioid-abuse-crisis
24.	StreetRx Study: One Year Later, New OxyContin Shows Lower Black-Market Price Than Old Crushable Version. BusinessWire. November 16, 2011. Accessed June 28, 2019, https://www.businesswire.com/news/home/20111116006249/en/StreetRx-Study-Year-New-OxyContin-Shows-Black-Market
25.	Castillo T. April 8, 2013. Big Pharma Company Jacks Up Price of Overdose Life Saver by 1100%: Now, More People Will Die. AlterNet. Accessed June 28, 2019, https://www.alternet.org/2013/04/big-pharma-company-jacks-price-overdose-life-saver-1100-now-more-people-will-die/
26.	Miron JA. Legalizing Opioids Would Dramatically Reduce Overdoses. The Foundation for Economic Education. Accessed June 28, 2019, https://www.valuewalk.com/2017/11/legalizing-opioids-dramatically-reduce-overdoses/
27.	Paperny, AM July 14, 2014. How pilfered Canadian pills are fuelling a U.S. health crisis. Accessed June 28, 2019, https://globalnews.ca/news/1441882/how-pilfered-canadian-pills-become-a-hot-u-s-commodity/
28.	Mens, Y. June 25, 2018. Etats-Unis: les overdoses tuent plus que les armes à feu. ALTERNATIVES ECONOMIQUES N°379. Accessed June 28, 2019, https://www.alternatives-economiques.fr/etats-unis-overdoses-tuent-plus-armes-a-feu/00085167
29.	Freyer, FJ. April 18, 2015. Researchers use black-market drug website to gauge public health. Boston Globe. Accessed June 28, 2019, https://www.bostonglobe.com/metro/2015/04/17/crowd-sourcing-website-reveals-black-market-drug-prices-but-its-purpose-public-health/cSMUlc9JrURxckanwygfFN/story.html

5. Broadcast Radio Mentions
30.	Brookland J, Hochberg A. February 1, 2018. The Patients, Prescribers, And Politics Behind NC's Opioid Crisis. WUNC. Accessed June 28, 2019, https://www.wunc.org/post/patients-prescribers-and-politics-behind-ncs-opioid-crisis
31.	Wolfram J. January 23, 2018. Penn State research links opioid deaths to economic hardship, natural disasters. WHYY. Accessed June 28, 2019, https://whyy.org/articles/penn-state-research-links-opioid-deaths-economic-hardship-natural-disasters/


VI. TEACHING RECORD

(a)  Student mentoring 
1. Member of Dissertation Committee
	Apostolos Alexandridis (2018, UNC Department of Epidemiology)
      Jessica Young (present, UNC Department of Epidemiology)
      Phyo Hytoo (present, UNC Department of Epidemiology)
	Clark Freifeld, (2015, Boston Univeristy Department of Biomedical Engineering)

2. Master’s Paper Reader
Two students in Health Behavior and Health Education, UNC School of Public Health 2007, 2009, approximately. 


3. Practicum/Fellowship Mentor
Alex Gertner (present, MD,MPH-candidate at UNC)
Aseem Kaul (present, MD,MPH-candidate at UNC)

          	VII. FUNDING
(a)  Active Grants
Ongoing Research Support:

1.   Dasgupta N (PI), Slavova, S (co-PI) 
HHSF223201810183C (FDA). 					09/28/2018 – 09/27/2022
$3,205,422 (total funding; direct costs: $2,133,84) 
Methodological Advances in Evaluating Abuse Deterrent Opioid Analgesics

2.   Ranapurwala S (PI), Dasgupta N, Naumann R, Shanahan M, Carey T, Chelminski P, Marshall S
1R01CE0030090100 (CDC). 					09/30/2018 – 09/29/2021
$2,039,525 (total funding; direct costs: $1,390,047)
Evaluation of state-mandated acute and post-surgical pain-specific opioid prescribing guidelines

3.   Ringwalt C (PI), Dasgupta N 
7-312-0213618-52523L (RTI Subaward) 			09/30/2015 - 09/29/2020
$465,228 (total; Direct: $306,071)
Evaluation of Prescription Drug Overdose Prevention for States Program
   
4.   Jonsson-Funk, M (PI) Chidgey B, Young J, Hudgens M, Dasgupta N, Stürmer T, Pate V
1-R36-DA045885-01 (NIH NIDA)					04/01/2018- 03/31/2020
$73,923
Identifying opportunities to reduce unnecessary opioid exposure and prevent iatrogenic addiction after outpatient surgery

5.   Tropsha, A (PI), Dasgupta, N (co-PI)				
U01 CA207160 (NIH)						08/15/2016 – 08/31/2019
$1,287,431 (total funding; direct costs: $900,000)
Drug Repurposing for Cancer Therapy: From Man to Molecules to Man


(b)  Completed Grants: 

1.	Dasgupta N. Workpackage Lead, General Advisory Board
Innovative Medicines Initiative Joint Undertaking Grant# 115632    09/01/2014 - 12/31/2017
€6,071,620 (approximately $6,911,622)
WEB-RADR: Recognizing Adverse Drug Reactions
. 
2.	Dasgupta N (PI)
HHSF223201400184C (FDA)					     09/01/2014 - 08/31/2017
$1,084,820
Enhancing tobacco surveillance through online monitoring

3.	Ringwalt, C (PI), Dasgupta N (Statistical Analyst)
U01CE002162 (CDC) 						     12/01/2012 – 11/30/2016
$137,103 (total subaward funding; direct costs: $92,637)
Evaluation of a community-based initiative to prevent opioid overdose

4.	Dasgupta N (PI)		 
HHSF223201310211C (FDA)					     09/01/2013 – 08/31/2016
$1,719,206
Mining social media for public-health risks in foreign drug and food supply chains. 

5.	Dasgupta N (PI)
HHSF223201210194C (FDA)					    08/01/2012 – 07/31/2015
$800,612		
Mining Social Media for Adverse Event Surveillance

6.	Dasgupta N (co-PI)		
HHSF223201210016C (FDA)					    09/01/2011 – 08/31/2014
$329,975
Develop a Mobile Application for Submitting Medical Device Reports to FDA 


7.	Ringwalt C (PI), Casteel C, Bowling J, Garrettson M, Dasgupta N 
2012-R2-CX-0002 (DOJ) 						     01/01/2013- 12/31/2014
$249,983
Identifying High Risk Prescribers Using PDMP Data: A Tool for Law Enforcement

8.	Ringwalt C (PI), Dasgupta N					    08/01/2015 - 06/30/2016
CCNC/KBR Sub 20150526 (Kate B. Reynolds Charitable Trust)
$92,000 (total; direct: $92,000) 
A Process and Outcome Evaluation of North Carolina Chronic Pain Initiative

9.	Ringwalt, C (PI), Dasgupta N
RWJF 20110726 (Robert Wood Johnson Foundation) 		   12/01/2011 – 05/31/2013
$146,179 (total; Direct: $134,472) 
Assessing the Effectiveness of Prescription Drug Monitoring Programs



	VIII. PROFESSIONAL SERVICE

A. Service to Discipline
1. Grant Reviewer 
 National Center for Injury Prevention and Control, Centers for Disease Control and Prevention (2016) 

2. Journal Editorships 
Pain Medicine, Associate Editor, (2008-present)
	American Journal of Public Health, Associate Editor for Surveillance and Survey Methods (July 2019-present)

3. Manuscript Reviewer (past 2 years)
American Journal of Public Health, Associate Editor (2019-present)
Addiction
Addictive Behaviors
American J. of Preventative Medicine
American Journal of Public Health
The British Medical Journal
Clinical Toxicology
Drug and Alcohol Dependence
Drug Safety
International Journal of Drug Policy
Journal of Drug Issues
Journal of Addiction Medicine
The Lancet Psychiatry
Substance Abuse Treatment, Prevention and Policy
Preventive Medicine
Pharmacoepidemiology & Drug Safety
Therapeutic Advances in Drug Safety


4. Consultant 
RADARS System, Rocky Mountain Poison and Drug Center, Denver Health, Denver, Colorado (2005-present, intermittently)
	The Researched Abuse, Diversion and Addiction Related Surveillance System is the largest international source of timely and geographically specific information on prescription drug abuse. The data are used to make regulatory decisions in many countries. My role has evolved over a decade and half, including study design, questionnaire development, data analysis, statistical methods development, scientific writing and presentations.

	Standard Disclosure: The RADARS System is the property of Denver Health and Hospital Authority, a political subdivision of the State of Colorado (United States of America). The RADARS System is supported by subscriptions from pharmaceutical manufacturers, governmental and non-governmental agencies for data, research and reporting services. Subscribers do not participate in data collection nor do they have access to raw data; Denver Health retains exclusive ownership of all data, databases and systems. Employees are prohibited from financial relationships with any biopharmaceutical company.

5. Abstract Reviewer 
ISPE Conference Abstract reviewer
HRC Conference Abstract reviewer

6. Expert Committees
Member of WHO Secretariat, Expert Committee on Drug Dependence (2012)
FDA Advisory Committee, Drug Safety and Risk Management (2018-present) 
Scientific Advisory Board, RADARS System (2014-present)


7. Non-profit Boards
Harm Reduction Coalition (non-profit), Chair, Board of Directors, (2008-present)	
North Carolina Harm Reduction Coalition (non-profit), Board of Directors, (2007-2013)
Project Lazarus (non-profit), Board of Directors, (2010)
